Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 11 July 2019, 11:00 HKT/SGT
Share:
    

Source: Novotech Health Holdings Pte Ltd
Novotech CRO partners Skin Research Institute of Singapore (SRIS) for Skin Disorder Research

SINGAPORE / TOKYO, July 11, 2019 - (ACN Newswire) - Novotech, the award-winning Asia-Pacific CRO, has further strengthened its presence in the region through a Partnership with the Skin Research Institute of Singapore (SRIS). With this partnership, the two groups will be working together to promote combined capabilities in skin research clinical trials.

SuLyn Yip, Novotech Country Manager, and Dr Steven Thng, Executive Director of SRIS, signing the Partnership.


The Partnership formalizes a long-standing working relationship between the two, enabling closer collaboration to ensure the high priority start-up of new projects, and cooperation in clinical trial promotion, business development, networking opportunities, clinical operation, training, and feasibility assessment.

SRIS was established as a collaboration between Agency for Science, Technology and Research (A*STAR), National Healthcare Group (NHG) and Nanyang Technological University (NTU) to conduct high impact, inter-disciplinary skin research that would translate into improved health outcomes and quality of life.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to bring unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

Novotech CEO Dr John Moller said the Partnership with SRIS will support the increasing demand from biotech clients for skin disorder studies in the Asia-Pacific region.

Please visit the Skin Research Institute of Singapore (SRIS)at https://www.a-star.edu.sg/sris/About-SRIS.

About Novotech:
Headquartered in Sydney, Novotech CRO is the internationally recognized Asia Pacific contract research organization (CRO) instrumental in hundreds of clinical trials across the region. https://novotech-cro.com/welcome
Check if Asia Pacific is right for your next study: https://novotechcro.typeform.com/to/Uwizka
For RFP enquiries, please fill out the form available at www.novotech-cro.com/contact-us-0

Media contact:
communications@novotech-cro.com
Susan Fitzpatrick-Napier
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech Health Holdings Pte Ltd
Feb 15, 2023 09:00 HKT/SGT
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 10, 2023 19:00 HKT/SGT
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 3, 2023 13:00 HKT/SGT
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires European CRO, Strengthens Global Operations
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
Dec 20, 2022 11:00 HKT/SGT
Novotech is Gold Sponsor at Biotech Showcase 2023
Dec 15, 2022 10:00 HKT/SGT
Data Shows 50% of New Trials Have Sites in Asia Pacific
Dec 6, 2022 11:00 HKT/SGT
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Nov 11, 2022 17:00 HKT/SGT
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
Oct 25, 2022 18:00 HKT/SGT
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: